Glen Eagle Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Glen Eagle Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-18	Closed	-$1.62K	–	947
2020 Q1	$1.62K	Hold	18	–	–	﹤0.01%	724
2019 Q4	$1.95K	Hold	18	–	–	﹤0.01%	781
2019 Q3	$1.76K	Hold	18	–	–	﹤0.01%	717
2019 Q2	$2.36K	Hold	18	–	–	﹤0.01%	686
2019 Q1	$2.43K	Hold	18	–	–	﹤0.01%	638
2018 Q4	$1.75K	Hold	18	–	–	﹤0.01%	637
2018 Q3	$2.5K	Hold	18	–	–	﹤0.01%	612
2018 Q2	$2.23K	Hold	18	–	–	﹤0.01%	600
2018 Q1	$2.01K	Buy	+18	New	+$2.15K	﹤0.01%	587
2017 Q4	–	Sell	-26	Closed	-$3.65K	–	681
2017 Q3	$3.65K	Buy	+26	New	+$3.53K	﹤0.01%	546

Other funds holding ALXN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Glen Eagle Advisors's ALXN Position: Q2 2020 in Review

Glen Eagle Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q2 2020, closing a stake of 18 shares — an estimated $1.62K sold.

Glen Eagle Advisors first reported a position in ALXN in Q3 2017 and held it in 10 quarters. The position peaked at $3.65K in Q3 2017. 707 funds tracked by Wall St. Rank hold ALXN as of Q2 2020.

Glen Eagle Advisors reported no remaining Alexion Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Glen Eagle Advisors sold 18 Alexion Pharmaceuticals shares in Q2 2020, an estimated $1.62K.
Glen Eagle Advisors first reported a position in Alexion Pharmaceuticals in Q3 2017 and held it in 10 quarters.
Glen Eagle Advisors's Alexion Pharmaceuticals position peaked at $3.65K in Q3 2017.
707 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2020.

Based on Glen Eagle Advisors's 13F filing for Q2 2020, filed 13 Aug 2024.